Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 5, 2009, Pages 907-916

  Corazzelli, Gaetano ^a   Capobianco, Gaetana ^a   Arcamone, Manuela ^a   Ballerini, Pier Ferruccio ^b   Iannitto, Emilio ^c   Russo, Filippo ^a   Frigeri, Ferdinando ^a   Becchimanzi, Cristina ^a   Marcacci, Gianpaolo ^a   De Chiara, Annarosaria ^a   Pinto, Antonio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Internal Medicine Unit 2   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

Author keywords

Gemcitabine; Non Hodgkin lymphoma; Oxaliplatin; Rituximab; Salvage treatment

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GEMCITABINE; OXALIPLATIN; RITUXIMAB;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAILURE FREE SURVIVAL; FEMALE; HUMAN; INFECTION; LARYNX DISORDER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PHARYNX DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SALVAGE THERAPY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; RECURRENCE; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 69049106407     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-0941-9     Document Type: Article

References (45)

1. B Seyfarth A Josting M Dreyling N Schmitz 2006 Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease Br J Haematol 133 1 3 18
2. H Schulz JF Bohlius S Trelle N Skoetz M Reiser T Kober et al. 2007 Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis J Natl Cancer Inst 99 9 706 714
3. CH Moskowitz JR Bertino JR Glassman EE Hedrick S Hunte N Coady-Lyons et al. 1999 Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma J Clin Oncol 17 12 3776 3785
4. PL Zinzani M Tani AL Molinari V Stefoni E Zuffa L Alinari et al. 2002 Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients Haematologica 87 8 816 821
5. EJ Rodriguez-Monge F Cabanillas 1997 Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience Hematol Oncol Clin North Am 11 5 937 947
6. T Kewalramani AD Zelenetz SD Nimer C Portlock D Straus A Noy et al. 2004 Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma Blood 103 10 3684 3688
7. TE Witzig SM Geyer PJ Kurtin JP Colgan DJ Inwards IN Micallef et al. 2008 Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group Leuk Lymphoma 49 6 1074 1080
8. C Thieblemont B Coiffier 2007 Lymphoma in older patients J Clin Oncol 25 14 1916 1923
9. W Plunkett P Huang YZ Xu V Heinemann R Grunewald V Gandhi 1995 Gemcitabine: metabolism, mechanisms of action, and self-potentiation Semin Oncol 22 4 Suppl 11 3 10
10. C Dumontet F Morschhauser P Solal-Celigny F Bouafia E Bourgeois C Thieblemont et al. 2001 Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma Br J Haematol 113 3 772 778
11. A Fossa A Santoro W Hiddemann L Truemper N Niederle S Buksmaui et al. 1999 Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma J Clin Oncol 17 12 3786 3792
12. RJ Soiffer MA Caligiuri C Tondini GP Canellos 1989 High-dose cytosine arabinoside in relapsed and refractory non-Hodgkin's lymphoma. Limited role as a single agent Cancer 64 10 2014 2018
13. I Chau M Harries D Cunningham M Hill PJ Ross CD Archer et al. 2003 Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma Br J Haematol 120 6 970 977
14. M Crump T Baetz S Couban A Belch D Marcellus K Howson-Jan et al. 2004 Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) Cancer 101 8 1835 1842
15. Ng M, Waters J, Cunningham D, Chau I, Horwich A, Hill M et al (2005) Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer 92:1352-1357
16. N Germann S Brienza M Rotarski JF Emile M Di Palma M Musset et al. 1999 Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients Ann Oncol 10 3 351 354
17. E Raymond S Faivre S Chaney J Woynarowski E Cvitkovic 2002 Cellular and molecular pharmacology of oxaliplatin Mol Cancer Ther 1 3 227 235
18. Y Oki P McLaughlin B Pro FB Hagemeister A Bleyer E Loyer et al. 2005 Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma Cancer 104 4 781 787
19. S Faivre E Raymond JM Woynarowski E Cvitkovic 1999 Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines Cancer Chemother Pharmacol 44 2 117 123
20. C Kollmannsberger J Beyer R Liersch P Schoeffski B Metzner JT Hartmann et al. 2004 Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group J Clin Oncol 22 1 108 114
21. P Bidoli SC Stani L Mariani D De Candis D Cortinovis S Aglione et al. 2004 Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer Lung Cancer 43 2 203 208
22. G Corazzelli G Capobianco F Frigeri F Russo A Pinto 2002 Combination of gemcitabine and oxaliplatin (GEMOX) in refractory and relapsed NHL Ann Oncol 13 Suppl 2 555a
23. S Woehrer M Hejna C Skrabs J Drach CC Zielinski U Jaeger et al. 2005 Rituximab, Ara-C, dexamethasone and oxaliplatin is safe and active in heavily pretreated patients with diffuse large B-cell lymphoma Oncology 69 6 499 502
24. C Emmanouilides AR Jazirehi B Bonavida 2002 Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine Cancer Biother Radiopharm 17 6 621 630
25. MR Smith I Joshi F Jin C Obasaju 2005 Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice BMC Cancer 5 103
26. T El Gnaoui J Dupuis K Belhadj JP Jais A Rahmouni C Copie-Bergman et al. 2007 Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy Ann Oncol 18 8 1363 1368
27. A Lopez A Gutierrez A Palacios I Blancas M Navarrete M Morey et al. 2008 GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study Eur J Haematol 80 2 127 132
28. Cabanillas F, Liboy I, Rodriguez-Monge E, Pavia O, Robles N, Maldonado N et al (2008) GROC (gemcitabine, rituximab, oxaliplatin combination) plus pegfilgrastim is less toxic and as active as DHAP and ESHAP for relapsed aggressive non-Hodgkin's lymphoma (NHL). J Clin Oncol 26(suppl) (abstract 8530)
29. NL Harris ES Jaffe J Diebold G Flandrin HK Muller-Hermelink J Vardiman et al. 2000 The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November, 1997 Hematol J 1 1 53 66
30. BD Cheson SJ Horning B Coiffier MA Shipp RI Fisher JM Connors et al. 1999 Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group J Clin Oncol 17 4 1244
31. WM Hryniuk M Goodyear 1990 The calculation of received dose intensity J Clin Oncol 8 1935 1937
32. S Marce M Molina-Arcas N Villamor FJ Casado E Campo M Pastor-Anglada et al. 2006 Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma Haematologica 91 7 895 902
33. E Ortega-Paino J Fransson S Ek CA Borrebaeck 2008 Functionally associated targets in mantle cell lymphoma as defined by DNA microarrays and RNA interference Blood 111 3 1617 1624
34. J Rodriguez A Gutierrez A Palacios M Navarrete I Blancas J Alarcon et al. 2007 Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma Leuk Lymphoma 48 11 2172 2178
35. T El Gnaoui J Dupuis B Joly K Belhadj A Rahmouni C Copie-Bergman et al. 2004 Rituximab, gemcitabine and oxaliplatin (R-GEMOX): a promising regimen for refractory/relapsed B-Cell lymphoma Blood 104 11 2483a
36. R Peto MC Pike P Armitage NE Breslow DR Cox SV Howard et al. 1977 Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples Br J Cancer 35 1 1 39
37. M Pfreundschuh J Schubert M Ziepert R Schmits M Mohren E Lengfelder et al. 2008 Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) Lancet Oncol 9 2 105 116
38. B Sirohi D Cunningham A Norman K Last I Chau A Horwich et al. 2007 Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL) Hematology 12 2 149 153
39. F Morschhauser S Depil E Jourdan M Wetterwald R Bouabdallah G Marit et al. 2007 Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma Ann Oncol 18 2 370 375
40. SS Jacobs E Fox C Dennie LB Morgan CL McCully FM Balis 2005 Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates Clin Cancer Res 11 4 1669 1674
41. JZ Kerr SL Berg R Dauser J Nuchtern MJ Egorin L McGuffey et al. 2001 Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates Cancer Chemother Pharmacol 47 5 411 414
42. M Bjorkholm H Hagberg H Holte S Kvaloy L Teerenhovi H Anderson et al. 2007 Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up Ann Oncol 18 6 1085 1089
43. F Lokiec 2006 Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention Ann Oncol 17 Suppl 4 iv33 iv36
44. G Corazzelli F Russo G Capobianco G Marcacci P Della Cioppa A Pinto 2006 Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study Ann Oncol 17 Suppl 4 iv18 iv24
45. G Corazzelli G Capobianco G Marcacci F Frigeri M Arcamone C Becchimanzi et al. 2008 Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective salvage regimen for relapsed and refractory Hodgkin and non-Hodgkin's lymphoma: results of a pilot study Ann Oncol 19 supplement 4 iv235